Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
-
New hope for hemophilia b: Long-Lasting clotting factor under study
Disease control OngoingThis study tests a new drug called rIX-FP, which is a long-lasting clotting factor, in 23 Chinese men with hemophilia B. The goal is to see how well it prevents and treats bleeding episodes when given regularly. Participants receive the drug as a routine shot to keep their clotti…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 17, 2026 04:43 UTC
-
New antibody shot tested for immune-deficient patients
Disease control OngoingThis study tests a medicine called IgPro20, given as a shot under the skin, in 8 adults with primary immunodeficiency (PID) who have never received antibody therapy before. The goal is to see how the drug works in the body and whether it is safe. Participants must be 18 or older …
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New HAE drug switch study aims for safer monthly prevention
Disease control OngoingThis study looks at whether it is safe for people aged 12 and older with hereditary angioedema (HAE) to switch from their current preventive medicine to a new monthly injection called garadacimab. About 18 participants will receive garadacimab for around 3 months, and researchers…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for chinese hemophilia patients: phase 3 trial of Long-Lasting clotting factor
Disease control OngoingThis study tests a new form of factor VIII (a blood-clotting protein) in Chinese men and boys with severe hemophilia A. The goal is to see how well the treatment prevents bleeding episodes and how safe it is when given 2 to 3 times per week. Participants must have already receive…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC